News & Events

Corporate Presentation

Corporate Presentation - March 2020

News Releases

Year

Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

May 4, 2020

Acquisition of Stemline establishes Menarini’s presence in the U.S. biopharmaceutical oncology market Menarini will support further development of Stemline’s ELZONRIS ® and enable global expansion by leveraging its commercial infrastructure in Europe and other ex- U.S.

Additional Formats

PDF Version

Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results

March 13, 2020

Net revenue for ELZONRIS® was $11.8 million for the fourth quarter Conference call and live webcast scheduled for Monday, March 16 th , at 8:00 AM ET NEW YORK , March 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the

Additional Formats

PDF Version

Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020

March 11, 2020

NEW YORK , March 11, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the company will host a conference call and webcast on Monday,

Additional Formats

PDF Version

Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference

February 26, 2020

NEW YORK , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that management will present at the Cowen 40 th Annual Health Care

Additional Formats

PDF Version

Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers

January 13, 2020

NEW YORK , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced preliminary net revenues for 2019, as well as outlined key BPDCN

Additional Formats

PDF Version